二肽酶IV在胃癌中的表达及临床意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1418 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：检测二肽酶IV（DPP IV）在胃癌组织中的表达，探讨其在胃癌预后中的价值。方法：收集本院手术后的胃癌组织及对应癌旁正常组织112例，用免疫组织化学方法定性比较胃癌组织及癌旁正常胃黏膜组织中DPP IV的表达；Western blot定量比较胃癌组织及癌旁正常组织中DPP IV蛋白的表达。结果：免疫组织化学结果示DPP IV在癌旁正常组织中有3例（占2.7%）表达缺失；胃癌组织中有78例（占69.6%）表达缺失；Western blot结果示DPP IV在胃癌组织中的含量明显低于癌旁正常组织；多因素分析示DPP IV是胃癌不良预后的独立预测因子（P＜0.001）。结论：DPP IV表达缺失是胃癌不良预后的独立预测因子。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	田杰
	张志安
	孙国兴
	肖保增
	张文超
	杨继涛
	张庆永
	尹晓
	耿国旺

关键词 ：二肽酶IV, 胃肿癌, 病理学, 预后

Abstract：Objective: To evaluate the expression of dipeptidyl peptidase IV (DPP IV) in gastric carcinoma tissue and matched para-tumor tissues, then its clinical pathologic significance for gastric carcinoma was investigated. Methods: One hundred and twelve cases gastric carcinomas tissues and the same number of matched para-tumor tissues were selected, expressive difference of DPP IV gene between carcinoma tissues and their matched para-tumor tissues was measured by immunohistiochemistry; with protein concentration level of DPP IV measured by Western blotting methods. Results: The expressive loss number for DPP IV was 3 (2.7%) in 110 normal gastric tissues, while lossed in 78 gastric carcinomas; and the level of DPP IV decreased obviously in DPP IV positive tissues; DPP IV is an independent prognostic factor of gastric carcinoma by multiple factor analysis. Conclusion: Loss of DPP IV’s expression is an independent poor prognostic factor of gastric carcinoma.

Key words： dipeptidyl peptidase IV stomach neoplasm pathology prognosis

收稿日期: 2016-03-05

作者简介: 田杰（1977-），男，河北清河人，主治医师。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2017/V47/I2/140

[1] 邹文斌, 李兆申. 中国胃癌发病率及死亡率研究[J]. 中国实用内科杂志, 2014, 34(4): 408-415.
[2] CARCAS L P. Gastric cancer review[J]. J Carcinog, 2014, 13: 14.
[3] PIAZUELO M B, CORREA P. Gastric cancer: overview[J].Colomb Med (Cali), 2013, 44(3): 192-201.
[4] ITOU M, KAWAGUCHI T, TANIGUCHI E, et al. Dipeptidyl peptidase -4: A key player in chronic liver disease[J].World J Gastroenterol, 2013, 19(15): 2298-2306.
[5] ZHONG J, RAO X, RAJAGOPALAN S. An emerging role of dipeptidyl peptidase 4 (DPP-4) beyond glucose control:potential implications in cardiovascular disease[J]. Atherosclerosis 2013, 226(2): 305-314.
[6] ZHENG T, BASKOTA A, GAO Y, et al. Increased plasma DPP4 activities predict new-onset hyperglycemia in Chinese over a four-year period: possible associations with inflammation [J]. Metabolism, 2014, 64(4): 498-505
[7] LEE S A, KIM Y R, YANG E J, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus[J]. J Cli Endocrinol Metab, 2013, 98(6): 2553-2561.
[8] 王忠民, 卢永科. DPPIV基因影响卵巢癌细胞生物学行为的机制探讨[J]. 中国医药指南, 2011, 9(10): 29-32.
[9] KOIVISTO V. Discovery of dipeptidyl-peptidase IV——a 40 year journey from bench to patient[J]. Diabetologia, 2008, 51(6): 1088-1089.
[10] YU D M, SLAITINI L, GYSBERS V, et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding[J]. Scand J Immunol, 2011, 73(2): 102-111.
[11] BROXMEYER H E, HOGGATT J, O’LEARY H A, et al.Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis[J]. Nat Med, 2012, 18(12): 1786-1796.
[12] SHIOBARA T, CHIBANA K, WATANABE T, et al. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells[J]. Respir Res, 2016, 17: 28.
[13] KACER A, ARIKOK A T, KOKENEK UNAL T D, et al.Stromal expression of CD34, α-smooth muscle actin and CD26/DPPIV in squamous cell carcinoma of the skin: A comparative immunohistochemical study[J]. Pathol Oncol Res, 2012, 18(1): 25-31.
[14] NAZARIAN A , LAWLOR K, YI S S, et al. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer[J]. Mol Cell Proteomics, 2014, 13(11): 3082-3096.
[15] VARONA A, BLANCO L, PEREZ I, et al. Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent[J]. BMC Cancer, 2010, 10: 193.
[16] BARREIRA DA SILVA R, LAIRD M E, YATIM N, et al. Dipeptidyl peptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy[J]. Nat Immunol, 2015, 16(8): 850-858.
[17] OHNUMA K, HATANO R, MORIMOTO C, et al. DPP4 in anti-tumor immunity: going beyond the enzyme[J]. Nat Immunol, 2015, 16(8): 791-792.
[18] STULC T, SEDO A. Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?[J]. Diabetes Res Clin Pract, 2010, 88(2): 125-131.
[19] YU D M, YAO T W, CHOWDHURY S, et al. The dipeptidyl peptidase IV family in cancer and cell biology[J]. FEBS J,2010, 277(5): 1126-1144.
[20] XIONG S, WANG Q, ZHANG L, et al. Identification of candidate molecular markers of nasopharyngeal Carcinoma by tissue microarray and in situ hybridization[J]. Med Oncol, 2011, 28(1): 341-348.
[21] WESLEY U V, TIWARI S, HOUGHTON A N. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells[J]. Int J Cancer, 2004, 109(6): 855-866.
[22] 张梦真, 乔玉环, 索振河, 等. 卵巢上皮性癌组织中二肽基肽酶IV蛋白和mRNA的表达[J]. 郑州大学学报, (医学版), 2009, 44(5): 1099-1022.
[23] SANCHEZ-OTERO N, RODRIGUEZ-BERROCAL F J,DE LA CADENA M P, et al. Exalution of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease [J]. Sci Rep, 2014, 4(2): 3999.